Epidemiological characteristics and regional disparities of lung cancer incidence and mortality in China
- VernacularTitle:中国肺癌发病与死亡流行特征及地区差异
- Author:
Hongrui WANG
1
;
Ruifeng XU
1
;
Zeyuan ZHAO
1
;
Guochao ZHANG
1
;
Na REN
1
;
Yun CHE
1
;
Liang ZHAO
1
Author Information
1. Department of Thoracic Surgery, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021, P. R. China
- Publication Type:Journal Article
- Keywords:
Lung cancer;
incidence;
mortality;
cancer registry areas;
Joinpoint regression model
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2026;33(11):1759-1768
- CountryChina
- Language:Chinese
-
Abstract:
Objective To stratifiedly describe the burden of lung cancer incidence and mortality as well as urban-rural disparities in China, based on registry-estimated data from 2010 to 2016 and model-predicted data for 2022 and 2024, and to analyze the epidemiological characteristics of lung cancer in tumor registry areas across the eastern, central, and western regions of China from 2010 to 2019, thereby providing an evidence base for region- and population-specific prevention and control strategies. Methods Based on the annual reports of cancer incidence and mortality in China published by the National Cancer Center and the Chinese Cancer Registry Annual Reports from 2013 to 2022 (covering data years 2010-2019), lung cancer (ICD-10 codes C33-C34) incidence and mortality data were collected. Crude rates, China-age-standardized rates (ASRC), and world-age-standardized rates (ASRW) were employed to describe the disease burden. Joinpoint regression models were utilized to estimate the annual percentage change and average annual percentage change. Results Registry-estimated data from 2010 to 2016 showed that the number of new lung cancer cases nationwide increased from 606 000 to 828 100, with the crude incidence rate rising from 46.08 per 100 000 to 59.89 per 100 000, and the ASRC of incidence rising from 35.23 per 100 000 to 36.46 per 100 000. Concurrently, deaths increased from 486 600 to 657 000, with the crude mortality rate escalating from 37.00 per 100 000 to 47.51 per 100 000, and the ASRC of mortality showing a slight increase from 27.93 per 100 000 to 28.09 per 100 000. Model projections indicated that new cases would reach 1 060 600 in 2022 and 1 175 900 in 2024, with projected deaths of 733 300 and 743 300, respectively; the ASRC of incidence and mortality in 2024 were projected to be 43.09 per 100 000 and 25.30 per 100 000, respectively. Between 2010 and 2016, the ASRC of incidence in urban areas remained overall stable but increased significantly among females, while urban ASRC of mortality showed no statistically significant change; both the ASRC of incidence and mortality increased significantly in rural areas. Projections for 2022 and 2024 suggested a decline in age-standardized mortality rates in urban areas, whereas the mortality burden remained substantial in rural settings. From 2010 to 2019, the ASRW of incidence increased significantly while the ASRW of mortality decreased significantly in the eastern region; in the central region, incidence remained generally stable while mortality declined in the later period; in the western region, overall trends were not significant, though an upward trend in incidence among urban females and mortality among urban males was observed. Conclusion The disease burden of lung cancer in China remains substantial, with the rising incidence among females and the increasing mortality burden in rural areas warranting focused attention. Registry-estimated data and model-predicted values from diverse sources should be interpreted in a stratified manner. Lung cancer prevention and control should be reinforced by building upon sustained tobacco control and exposure factor mitigation. This entails implementing standardized low-dose computed tomography (LDCT) screening based on risk assessment, while strengthening the management of positive pulmonary nodules, early diagnosis and treatment, and the capacity for standardized diagnosis and treatment at the primary healthcare level.